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As obesity and type 2 diabetes are becoming an epidemic in westernized countries, the incidence and prevalence of obesity- and diabetes-
related co-morbidities are increasing. In type 2 diabetes ectopic lipid accumulation in the heart has been associated with cardiac dysfunction
and apoptosis, a process termed lipotoxicity. Since cardiovascular diseases are the main cause of death in diabetic patients, diagnosis and
treatment become increasingly important. Although ischaemic heart disease is a major problem in diabetes, non-ischaemic heart disease
(better known as diabetic cardiomyopathy) becomes increasingly important with respect to the impairment of cardiac function and mortality
in type 2 diabetes. The underlying aetiology of diabetic cardiomyopathy is incompletely understood but is beginning to be elucidated. Various
mechanisms have been proposed that may lead to lipotoxicity. Therefore, this review will focus on the mechanisms of cardiac lipid accumu-
lation and its relation to the development of cardiomyopathy.
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1. Introduction
Type 2 diabetic patients are at a significantly greater risk of developing
both micro- and macrovascular disease.1,2 Even after adjusting for
concomitant risk, diabetic individuals remained at increased risk of
heart failure. This phenomenon was first described by Rubler
et al.3,4 in 1972 in diabetic patients with heart failure but without
hypertension or coronary artery disease. Since then this phenomenon
has been confirmed by large epidemiological studies. This has led to
the recognition of a new clinical entity now termed ‘diabetic cardio-
myopathy’. This disease is defined by structural changes in the
heart, such as increased left ventricular (LV) mass, fibrosis and a
dilation of the ventricles5 in the absence of ischaemia or alterations
in blood pressure.3,6 Diabetic cardiomyopathy is mainly characterized
by diastolic dysfunction, which may precede the development of sys-
tolic dysfunction.7,8 Although the prevalence of this disease without
any other cardiovascular co-morbidities is still quite rare in type 2 dia-
betes,9,10 the co-incidence with micro- and macrovascular disease,
might aggravate the existing pathology and lead to an increased mor-
tality and morbidity in type 2 diabetes.11,12 Therefore, a better under-
standing and treatment of this disease is needed.
It has been well established that indeed the greater incidence of phys-
ical inactivity, hypertension and hyperlipidaemia in obese patients are the
main contributors to the development of cardiac disease in obesity and
type 2 diabetes.13,14 Furthermore, the reversal of these effects by redu-
cing body mass and introducing a more physically active lifestyle appear
to significantly reduce the risk of cardiovascular diseases.15,16 Nonethe-
less, the underlying mechanisms are incompletely understood. There are
many different theories about the mechanisms leading to structural
changes of the diabetic heart.17,18 As lipid accumulation and plasma
free fatty acid (FFA) levels are increased in the obese state and are nor-
malized after life-style intervention with a reduction in body mass, the
negative effects of lipid accumulation have gained more attention in
order to explain the aetiology of diabetic cardiomyopathy. Therefore,
in this review we will focus on lipotoxic mechanisms possibly leading
to diabetic cardiomyopathy in obesity and type 2 diabetes. Roughly
these mechanisms can be divided into two main categories (i) lipotoxic
mechanisms that impair cardiac energy metabolism and (ii) mechanisms
that lead to lipoapoptosis.
Regarding cardiac energy metabolism, O2 consumption of the heart
has been shown to be increased and ATP/O ratios to be lower in type
2 diabetic hearts and in hearts under fatty acid (FA) infusion, indicating
a decrease in cardiac efficiency in the prediabetic as well as in the dia-
betic state.19– 21 Possible underlying mechanisms will be discussed in
more detail in Section 3.1.
At the basis of cardiac lipotoxicity is the excessive accumulation of
fat or FA intermediates in cardiomyocytes. Therefore, understanding
cardiac lipid uptake and mechanisms involved in the upregulation of
cardiac lipid uptake is needed in order to understand the develop-
ment of cardiac lipid accumulation and ultimately cardiac lipotoxicity.
2. Why does fat accumulate in
cardiac muscle?
2.1 Role of FA uptake and transporters
Chronic overnutrition is associated with increased plasma concen-
trations of free fatty acids (FFA),22,23 which are probably due to an
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increased adipose tissue insulin resistance.24,25 A chronic nutrient
overload leads to an increase in adipose tissue, and if the storage
capacity and expandability of these adipocytes is low, the adipocytes
will become hypertrophic. This may in turn create local hypoxia
and lead to the release of pro-inflammatory factors. The latter has
been shown to be able to suppress insulin signaling. In insulin-resistant
adipocytes, lipolysis is incompletely suppressed, which causes an
increased release of FFAs (for a more detailed overview see
review25) leading to cardiac lipid accumulation.26 –28
The increase in plasma FFA has been associated with an increased
cardiac fatty acid (FA) uptake. For instance, in ob/ob mice (leptin-
deficient mice), obesity increased plasma FA availability and resulted
in an increased cardiac lipid content.29 This mechanism is not patho-
logical per se, as under physiological conditions such as fasting or exer-
cise, myocardial lipid content can be elevated significantly.30,31 This
illustrates that elevated circulating FFA levels augment cellular
uptake and stimulate storage of triglycerides. However, this raises
the question of how FFA uptake is regulated in cardiac muscle and
if this regulation is altered in obesity and type 2 diabetes.
Uptake of plasma FFAs can occur through passive diffusion via a
so-called flip-flop mechanism.32 Transbilayer flip-flop is the process
by which lipids are moved between the two leaflets of the membrane
bilayer spontaneously.33 A protein-mediated process facilitates this FA
transport. For cardiac tissue there are three recognized groups of FA
transporting proteins: CD36 (human homologue of FA transporter
protein FAT), FABP-pm (plasma membrane fraction of FA-binding
protein) and FATP1,4 and 6 (FA translocase Protein 1, 4 and 6).34
In the heart FAT/CD36 and FABP-pm appear to be key transporters
involved in FA uptake.35 CD36 was shown to be responsible for up to
60% of the FA uptake in the heart.36 Overexpression of CD36 in
cardiac muscle increased the rate of FA uptake and increased FA
metabolism, whereas knockdown of CD36/FAT reduced FA uptake
and metabolism.37,38 Similar to GLUT4, CD36 is present in cellular ves-
icles and can be translocated to the cell membrane rapidly upon acute
stimulation by insulin, muscle contraction or AMP-kinase (AMPK) acti-
vation. This ability of CD36 to be able to translocate to the plasma
membrane and thereby stimulate FA uptake under certain conditions
is specific for CD36. Furthermore, CD36 can traffic between the endo-
somes and the nuclear membrane, whereas the other FA transport
proteins do not have this capability.39 Longer term regulation of
CD36 involves ubiquitination. It was shown that insulin attenuates ubi-
quitination, thereby increasing the availability of CD36 for translocation
and uptake of FFA. In contrast, FFA enhances ubiquination, thereby
increasing CD36 degradation and creating a negative feedback.40
Although total concentration of CD36 was unchanged in obesity
and diabetes, permanent translocation of CD36 to the plasma mem-
brane seemed to occur.41 –43 It is suggested that the resulting
increased uptake of FAs may lead to substrate competition with
glucose, and therefore CD36 may also play an important role in the
development of lipid-induced insulin resistance.41,42
Cardiac-specific FATP-1 overexpression has also been shown to
increase FA uptake by 4-fold and cardiac lipid accumulation by
2-fold.44 It has been speculated from studies in skeletal muscle that
FATP-1-facilitated FA uptake mainly serves to fuel oxidation, though
evidence concerning the heart is still lacking. Also, very little is
known about the physiological stimuli that may regulate the
expression of FATP-1.45 FATP-4 is expressed in cardiac tissue, but
the contribution to lipid uptake in cardiac tissue is still
undetermined.34,46
FATP-6 is only expressed in the heart and has been shown to
enhance FFA transport in cultured cardiomyocytes.47 FATP-6 only
promoted FA uptake slightly when expressed in yeast, and its role
in vivo is still under debate.48,49
2.2 FA storage
Facilitated uptake of circulating FAs is an important regulatory step
that affects overall cardiac fat content. However, next to FA uptake,
triglyceride storage and lipolysis inside cardiomyocytes will ultimately
determine the fate of the FAs.
One of the genes that has been intensively studied in the context of
cardiolipotoxicity is Glycerol-3-phosphate acyltransferase (GPAT).
GPAT is the rate-limiting step in TG synthesis, which can be inhibited
by ACC-stimulated AMPK activation via malonyl-CoA. In some,50,51
although not all52 rodent models of diabetes, GPAT activity was
found to be enhanced in cardiac tissue. Interestingly, deletion of
GPAT1 protected mice from the effects of a high fat diet on cardiac dys-
function and fat accumulation.51 So far, it remains unclear whether
GPAT activity is increased in human diabetic cardiomyopathy.
Another gene that has received considerable interest is diglyceride
acyltransferase (DGAT). Thus, increased DGAT activity has been
linked to lipid accumulation and cardiomyopathy. Glenn et al.53
recently found increased lipid accumulation in a cardiomyocyte-
selective DGAT1 transgenic mouse model. On the other hand, when
DGAT1 overexpression was crossed with a model of lipotoxic cardio-
myopathy, it seemed to protect against the development of cardiac dys-
function.54 Therefore, it seems that DGAT might play a dual role in the
development of lipotoxic cardiomyopathy.
Ueno et al.55 investigated the role of HSL, which is involved in
lipolysis of TG and DAG. In this study heart-specific HSL overexpres-
sing transgenic mice (MHC-HSL) were used and diabetes was induced
by administration of streptozotocin. Diabetic MHC-HSL mice had no
lipid droplet formation in the heart upon a high fat diet, unlike the
wild-type (WT) animals, thus demonstrating that the regulation of
lipolysis is an important determinant of cardiac lipid content. Also,
ATGL deficiency has been associated with a severe form of cardiac
lipid accumulation and the development of cardiomyopathy both in
mice56,57 and in humans.58 Therefore, a decent function of ATGL
seems crucial for maintaining a normal cardiac function.
Taken together, a dysbalance between FA uptake, TG synthesis,
and lipolysis may result in net fat storage in the heart, ultimately
leading to cardiac fat accumulation. In Section 3.1.1 we will also
discuss how alterations in FA and glucose oxidation may affect
cardiac function and induce insulin resistance of the heart.
3. The association between cardiac
steatosis and cardiomyopathy in
type 2 diabetes
3.1 Impaired cardiac energetics
Low cardiac ATP production is associated with a decreased contrac-
tility in the absence of ischaemia.19,59 For cardiomyocyte contraction,
interactions between ATP and calcium are required in appropriate
amounts.60 Therefore, a decrease in ATP or impaired calcium hand-
ling, could drastically impair cardiac contractility (Figure 1).








niversity user on 28 Septem
ber 2021
3.1.1 Altered substrate metabolism
The notion that type 2 diabetes leads to an altered regulation of
cardiac metabolism is well established.61,62 In the prediabetic and dia-
betic states, myocardial O2 consumption and FA oxidation are
increased and cardiac efficiency is decreased.19,21 In type 2 diabetic
patients a 2-fold increase in cardiac palmitate oxidation and a 30–
40% decrease in glucose oxidation have been shown.20,21 In db/db
mice (mice with a defect in the leptin receptor) alterations in substrate
metabolism were paralleled by a decreased contractility eventually
leading to cardiomyopathy.61,63 Other studies, performed with iso-
lated working hearts of diabetic animals, confirmed that a high rate
of FA oxidation is associated with ventricular dysfunction.59,64 These
results strongly suggest a causative role for altered substrate metab-
olism in the development of cardiomyopathy in db/db diabetic hearts.
For a long time, it was thought that the Randle cycle was the main
contributor to the biochemical shift towards FA uptake and oxidation
in type 2 diabetes. Randle proposed that a higher rate of release of
FAs and ketone bodies for oxidation was responsible for the decrease
in glucose oxidation and uptake65. Though substrate competition
plays an important role in type 2 diabetes, increasing evidence
suggests that there are also some cellular maladaptations that are
important in the regulation of substrate oxidation. The gene regulat-
ory pathway of peroxisome proliferator-activated receptor alpha
(PPAR-a) was identified as an important determinant of the shift in
substrate metabolism in type 2 diabetes. In mice with
cardiac-restricted overexpression of PPARa (MHC-PPAR), it was
found that PPAR-a is involved in the upregulation of CPT-1 in mito-
chondria, which increases the uptake of long-chain fatty acid into
mitochondria and facilitates the FAs to undergo beta-oxidation.66 In
the same mouse model, the increase in FA oxidation was paralleled
by decreased LV function on a high-fat diet. Paradoxically, chronic
exposure to elevated FFAs seems to down-regulate PPAR-a in
rodent cardiomyocytes. This down-regulation has been proposed to
further decrease cardiac function by inhibition of FA oxidation and
increased intracellular fat accumulation.67,68 Human studies on
PPAR expression in the heart are scarce. Marfella et al.69 showed
an increased expression of sterol regulatory element-binding
protein 1c (SREBP1c) and PPAR-g in patients with the metabolic syn-
drome, which was associated with an increased fat accumulation in
the heart and poor cardiac function. Although PPAR-a was not
changed in these subjects, the increased expression of SREBP1c and
PPAR-g might indicate that there are some aberrations in PPAR-
regulated pathways, which lead to an increased fat uptake and
storage in the metabolic syndrome. Conversely, other studies such
as that of Anderson et al.,21 did not detect a change in PPAR-a
expression in the hearts of type 2 diabetes patients. Therefore, it
remains unclear whether these mechanisms found in animal studies
can be fully translated from animal studies to the human condition.
Although we focus on the negative effects of lipid accumulation in
this review, it is important to note that the fate of glucose and FAs
are intertwined. Besides inducing lipid accumulation and stimulating
fat oxidation, PPAR-a activation can also decrease glucose utilization
by increasing the expression of pyruvate dehydrogenase kinase 4
(PDK-4).70 It is hypothesized that this mechanism protects against
glucose overload in addition to the already present lipid overload
and thereby making the heart insulin resistant.65,71 This again contrib-
utes to a more rigorous shift in substrate metabolism towards FA oxi-
dation. In a chronic state, this lipid-induced PDK-4 activity leads to
increased intracellular glucose concentration, resulting in glucotoxicity.
Chronically, a high glucose concentration increases the flux through
the hexosamine biosynthethic pathway and increases N-acetyl-glucosa-
mine production. This has been associated with insulin resistance, ROS
production, hypertrophy and apoptosis in perfused hearts and cell
studies, thus augmenting the lipotoxic effects.72– 74
So it seems that the PPARa-induced increase in fat utilization in the
diabetic heart may initially serve as a compensatory mechanism to
adjust substrate oxidation to supply, though chronic derangements
in cardiac metabolism may have maladaptive consequences, including
glucotoxicity and functional cardiac abnormalities. However, the role
of these metabolic changes in the development of cardiac dysfunction
is poorly understood.
The shift in substrate oxidation itself is often hypothesized as one of
the main factors contributing to the development of contractile dys-
function in diabetes.75,76 It is suggested that reliance on FA oxidation
will reduce cardiac energy efficiency, and thereby contributes to car-
diomyopathy. Theoretically, more oxygen is required for the pro-
duction of ATP from FAs compared with glucose.77 Thus, when
shifting from 100% palmitate oxidation to 100% glucose oxidation, a
12% decrease in the amount of oxygen required for ATP synthesis
would occur.77 However, a total shift from fat to glucose oxidation
will never occur under physiological conditions. Therefore, while
increased concentrations of exogenous FAs resulted in a marked
Figure 1 Mechanisms involved in decreasing cardiac energetics.
(1) Change in substrate supply increases FA oxidation, decreases
glucose oxidation and reduces ATP/O ratios. Furthermore, increased
FA oxidation is associated with an increased ROS production. ROS
oxidizes lipids stored in the cytoplasm into lipid peroxides (2), indu-
cing cellular damage, as well as mitochondrial damage, further
decreasing mitochondrial function. The presence of FAs also stimu-
lates uncoupling (3), further decreasing energy production and con-
tractility (4). On the other hand, uncoupling may also be
cardioprotective by decreasing ROS production.
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increase in basal myocardial oxygen requirements,78,79 this increase in
oxygen requirement and accompanying decrease in ATP production is
too large to be explained solely by a shift from glucose to fat
oxidation.78
3.1.2 Mitochondrial uncoupling, dysfunction and ROS
production
Uncoupling describes the lowering of the proton gradient over the
inner mitochondrial membrane without production of ATP. In this
way, uncoupling lowers the production of mitochondrial ATP,
thereby making the heart less efficient, which could contribute to
the development of cardiac contractile dysfunction in type 2 diabetes.
In isolated hearts of ob/ob mice, perfusion with FFA compared with
glucose led to increased oxygen consumption and a reduced ATP/O
ratio. These changes in ATP/O ratio were too large to be accounted
for by changes in substrate metabolism, which was interpreted as
increased mitochondrial uncoupling.75,80 Indeed, the increase in FA
metabolism in these hearts was associated with an increased
expression of mitochondrial uncoupling proteins.81 Similar results
were found for db/db mice.63 It is known that FAs can induce uncou-
pling via PPAR-a-induced upregulation of UCP3.67 Also in humans,
the expression of UCP3 was related to circulating plasma FA
levels.82 In addition to an effect of FA on the induction of uncoupling
proteins, FAs themselves may also activate the process of mitochon-
drial uncoupling themselves.83,84 This uncoupling effect is due to a
cyclic movement of undissociated FAs with the release of protons
into the matrix.85,86
Though uncoupling might be detrimental for cardiac efficiency, a
protective function has also been described. It is hypothesized that
mitochondrial uncoupling serves to limit the production of reactive
oxygen species by the mitochondria, as it has been shown that mem-
brane potential displays a negative relationship with mitochondrial
ROS production.87,88 This suggests that a very mild lowering of the
proton gradient may already markedly lower the production of
ROS.20,89 ROS can damage mitochondria and other cellular com-
ponents by oxidizing proteins, converting lipids into reactive lipid per-
oxides, increase protein tyrosine nitration and damage DNA.90,91 If
extensive damage occurs, this can lead to mitochondrial dysfunction,
altered cellular function or even apoptosis. Mitochondrial ROS pro-
duction has been shown to impair contractility of cardiomyocytes in
vitro.92 Boudina et al.93 showed an increased mitochondrial H2O2 pro-
duction in cardiomyocytes of ob/ob mice. This was not only paralleled
by increased cardiac lipid accumulation and mitochondrial dysfunc-
tion, but also by an increase in ROS scavengers in the heart.63 Also
in db/db mice an increased ROS production was found, which was
associated with an increased apoptosis of cardiomyocytes.68,94 The
study of Anderson et al.21 is the only study in humans indicating an
increase in cardiac ROS production. They found that diabetic patients
have an increased mitochondrial H2O2 emission during oxidation of
lipid-based substrates compared with carbohydrate-based substrates
and depleted glutathione, which are evidence of persistent oxidative
stress in atrial tissue.21
As mentioned above, ROS can have direct negative effects on mito-
chondria, thereby impairing cardiac energetics. If ROS concentrations
are indeed elevated in the diabetic heart, these patients are expected
to be at increased risk for mitochondrial dysfunction. Indeed, it has
been shown that the intrinsic function of cardiac mitochondria in
type 2 diabetes is decreased. In mouse models of type 2 diabetes
and obesity, myocardial mitochondrial function and ATP synthesis
rates were impaired which was associated with cardiac dysfunction
and lipid accumulation.95– 97 Boudina et al.63 showed a decreased
intrinsic mitochondrial function in db/db mice, measured in permeabi-
lized cardiac fibres. This was paralleled by a decreased ATP pro-
duction, lower ATPase expression, and a 2.2-fold increase in cardiac
lipid accumulation. Palmitate infusion in these animals further deterio-
rated mitochondrial function, as uncoupled respiration increased and
ATP/O ratios decreased, thus indicating induction of mitochondrial
uncoupling in addition to the already existing deficit in mitochondrial
respiration.63 How et al.97 showed that cardiac efficiency, expressed
as the ratio of cardiac work [pressure–volume area (PVA)] over myo-
cardial oxygen consumption (MVO2), decreased as MVO2 increased
by around 86 and 57% in db/db and STZ-administered hearts, respect-
ively. In another study98 they showed that perfusing isolated working
hearts with a higher concentration of FAs did not change the perform-
ance or contractile efficiency, though it did increase oxygen consump-
tion, thus indicating an FA-induced increase in the unloaded MVO2.
This effect was more pronounced in the hearts of db/db mice.
These data suggest that increase in FA availability makes the heart
less efficient.
In human studies direct evidence of decreased cardiac mitochon-
drial function in type 2 diabetes comes from the study of Anderson
et al.21 They measured ex vivo mitochondrial respiratory capacity in
permeabilized myofibres derived from atrial tissue of type 2 diabetic
patients and found lower rates of respiration in diabetic patients.
These findings were paralleled by increased cardiac lipid accumulation,
indicating that lipid accumulation may be associated with impaired
mitochondrial function. Furthermore, impaired intrinsic mitochondrial
function of the diabetic heart is supported by studies using 31- P mag-
netic resonance spectroscopy (MRS) in humans. MRS can be used to
determine energy status of the heart in vivo non-invasively by deter-
mining the phosphocreatine/ATP ratio (PCr/ATP ratio). MRS exper-
iments demonstrated that type 2 diabetic patients had reduced PCr/
ATP ratios, suggesting that mitochondrial high-energy phosphate
metabolism may be impaired; however changes in the creatine pool
and increased ATP utilization, as opposed to ATP production, may
have also contributed to this observation.99– 101 Furthermore, it was
shown that in diabetic patients with normal morphology of the
heart, PCr/ATP correlates negatively with serum FFA99, indicating
that an increase in FFA availability might impair cardiac energy
reserves. On the contrary, studies with well-controlled type 2 diabetic
subjects do not show any changes in the PCr/ATP ratio.20,102 Differ-
ence in these findings may be due to differences in co-morbidities of
the study populations such as low glycemic control, high blood
pressure and dyslipedemia.
Another lipotoxic mechanism linking mitochondrial dysfunction
with cardiac structural changes is impaired calcium handling. Upon
electrical stimulation, calcium is released from the sarcoplasmic
reticulum in order for calcium to bind troponin C on the actin
filaments. This leads to changes in the contractile regulatory proteins
allowing interaction between actin and myosin cross-bridges. ATP is
required for initiating a new contractile cycle and for the re-uptake
of calcium in the sarcoplasmic reticulum via calcium-ATPase 2a.
Besides the insulin-induced changes in calcium fluxes, a
decrease in ATP production also leads to an impaired mitochondrial
calcium handling, which contributes to a decreased cardiac
contraction.60,103
In animal studies, calcium handling was altered in the type 2 diabetic
(db/db) state.59,104 Also, ob/ob mice had a slowed intracellular decay of
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calcium and impaired mitochondrial calcium handling upon electrical
stimulation, which was associated with increased intramyocellular
lipid accumulation in these cells.105,106 Upon high-fat feeding, it was
shown that impaired calcium handling due to a lower cardiac ATP
supply was the main cause of cardiac dysfunction in the absence of
apoptosis.107 Thus, while there is evidence that calcium handling is
impaired in type 2 diabetes and mitochondria have been shown to
play a part in impaired calcium handling in obesity models, it has
not been directly investigated whether the impaired Ca2+ handling
in diabetes is also caused by mitochondrial impairments.
Together, these data suggest that increased fat uptake in the heart
could lead to reduced energy efficiency by inducing mitochondrial
damage and uncoupling, increasing ROS production and via impair-
ment of mitochondrial calcium handling. These studies highlight the
importance of proper mitochondrial function in type 2 diabetes in
order to maintain a normal cellular homeostasis.
3.2 Lipoapoptosis
Besides changes in cardiac efficiency, lipoapoptosis may also contrib-
ute to the decreased function of the fatty heart. Lipoapoptosis can be
based on different mechanisms such as palmitate toxicity, ceramide
and DAG formation, endoplasmic reticulum (ER) stress, membrane
destabilization and inflammation (Figure 2).
3.2.1 Palmitate toxicity
Palmitate (a saturated FA) can induce apoptosis in isolated cardiomyo-
cytes, independent of ceramide formation.108,109 Although this tox-
icity of FA incubation in vitro has been implicated in the
pathophysiology of cardiovascular disease, the effects on cardiac myo-
cytes remain incompletely understood.
Several studies investigated the mechanisms through which palmi-
tate may induce apoptosis. It was shown that palmitate-induced acti-
vation of the stress-associated protein kinases induced apoptosis in
20% of the cardiomyocytes.110 Strikingly, it was found that the
effects on apoptosis through palmitate exposure in cardiomyocytes
were inhibited by titrating low concentrations of oleate.110 Further-
more, increasing mitochondrial uptake of palmitate with L-carnitine
decreased apoptosis, while decreasing uptake with the carnitine pal-
mitoyl transferase-1 inhibitor perhexiline almost doubled
palmitate-induced apoptosis.110 This indicates that cytosolic accumu-
lation of saturated FAs is detrimental for cellular function.
3.2.2 Ceramide formation
Ceramide-induced apoptosis is thought to be an important contribu-
tor to the development of lipotoxic cardiomyopathy. This concept
was based on several in vitro and in vivo studies. When FA oxidation
was reduced in vitro, intracellular triglycerides and ceramides were
increased and induced caspase-3 activity and DNA laddering.111,112
Figure 2 Possible mechanisms leading to lipoapoptosis in cardiomyocytes. (A1) Stored triglycerides in cardiomyocytes can be hydrolyzed, resulting
in (A2) diacylglycerols and FAs that can be metabolized in non-oxidative pathways. In that way, saturated FAs can be converted into ceramides. Cer-
amides can initiate lipoapoptotic pathways (A3) via cytochrome C release of the mitochondria and can inhibit the insulin-signaling pathway via PKC
resulting in IR. DAGs also induce IR via interference with the insulin-signaling pathways, but whether DAGs can also induce apoptosis in cardiac muscle
still remains unknown. Lipids that cannot be stored can also be integrated as saturated phospholipids in the membranes and induce imbalances in the
UFPR leading to ER stress (B1), which in turn (B2) can lead via mitochondrial pathways (C1) and cytochrome C release to lipoapoptosis. Also cyto-
kines from systemic and locally inflamed adipose tissue (D1) might induce cellular signaling and attract immune cells thereby inducing local inflam-
mation, leading to insulin resistance, cellular damage and apoptosis.
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In various rodent models of lipotoxic cardiomyopathy, diabetes, and
obesity, increased myocardial ceramide content has been observed
in association with cardiac dysfunction.66,68 For instance, in the
study of Park et al.113 the lipotoxic dilated cardiomyopathy of the lipo-
protein lipase (LPL)GPI mice was rescued by pharmacological inhi-
bition of ceramide synthesis via myriocin. This therapy restored
ceramide levels to WT levels and normalized substrate utilization of
the heart. Both changes were associated with the improvement of
cardiac function.113 Crossing the LPLGPI mice with LCB1+/2 mice
that have a deletion in the serine palmitoyltransferase enzyme (the
enzyme that initiates the conversion of fatty-acyl co-A into ceramides)
gave similar results to that of the administration of myriocin
alone.68,113 Thus, these data suggest that ceramides play an important
role in the development of lipotoxic cardiomyopathy.
There is only one human study that assessed the role of ceramides
in lipoapoptosis in the human heart. Baranowski et al.114 examined the
relationship between myocardial apoptosis and ceramide levels in
obese and type 2 diabetic patients. Compared with lean subjects,
the markers for apoptosis were higher in the myocardium of obese
patients and increased further in type 2 diabetic subjects. However,
ceramide and sphingoid base content were similar in both groups.
Furthermore, mRNA levels of enzymes involved in synthesis and
degradation of ceramides were markedly increased in both obese
and type 2 diabetic subjects. These results challenge the view that cer-
amides are the main determinant of apoptosis in the fatty heart of
obese and diabetic humans.
Besides inducing apoptosis, ceramides can acutely inhibit insulin-
stimulated glucose uptake, GLUT4 translocation and glycogen syn-
thesis.113 These effects appear to result from the ability of sphingolipid
to block activation of either insulin receptor substrate 1 or AKT/protein
kinase B. These effects could contribute to the vicious cycle of insulin
resistance and thereby aggravate the existing cardiac impairments.
3.2.3 Diacylglycerol formation
It is known that in obesity and diabetes, due to an oversupply in lipids,
DAGs can accumulate in different cellular compartments. It is
hypothesized that DAGs interfere with the insulin-signaling cascade
in the heart as they do in skeletal muscle,115 leading to a decreased
insulin-stimulated glucose uptake. Increased accumulation of DAG
activates protein kinase epsilon and d, which in turn interfere with
the insulin-signaling cascade. A 10 week high fat diet in C57BL/6
mice, resulted in a decreased insulin-stimulated glucose oxidation in
isolated working hearts. This was positively associated with increased
accumulation of myocardial DAG, a concomitantly increase in GPAT
and a decrease in DGAT, as well as an inhibition of insulin-signaling
molecules.116
Whether DAG can also exert direct lipotoxic effects by inducing
apoptosis in cardiac tissue remains unknown. Overexpression of
DGAT in the heart reduced DAG levels and had a cardioprotective
effect when crossed with a mouse model of cardiac lipotoxicity.
However, in this model neutral lipid storage was increased.
Besides the decrease in DAG levels, ceramide formation was
decreased by 35%. Therefore, it remains unclear whether the cardi-
oprotective effect was due to the lowering of DAG or ceramides
levels.54
3.2.4 Membrane destabilization and ER stress
Another potential lipotoxic mechanism that may be involved in dia-
betic cardiomyopathy is membrane destabilization and ER stress.117
The ER is a primary site for protein synthesis and folding. Most
secreted and transmembrane proteins fold and mature in the lumen
of the ER. Cells can adjust the protein-folding capacity of the ER,
thereby ensuring that the necessary proteins can maintain cellular
function in due time. The intracellular signalling pathway that mediates
this regulation has been named the unfolded protein response
(UFPR).118
In obesity, increased lipid delivery can stimulate an increased influx
of unfolded proteins in the ER, which can lead to a mismatch between
the UFPR and protein translation, inducing stress of the ER.118 ER
stress enhances calcium release and signaling to the mitochondria,
ultimately resulting in increased apoptosis.119
In mice with streptozotocin-induced diabetes, cardiac ER stress was
suggested by expression of ER chaperones and apoptosis was
detected 5 months after diabetes onset. Also, in models of type 2 dia-
betes it was shown that cardiomyopathy was associated with ER
stress. In db/db mice levels of the phosphorylated ER-stress makers
were significantly elevated compared with lean controls.120 It has
been shown in vitro that ER stress is enhanced in lipotoxicity. Cells
exposed to palmitate could rapidly convert palmitate into phospholi-
pids, which were integrated into the microsomal membranes. This
resulted in drastic membrane remodelling which was associated
with dramatic dilatation of the ER and redistribution of protein-folding
chaperones to the cytosol within 5 h, indicating compromised ER
membrane integrity and further enhancing ER stress.121 Although
there is no data on ER stress in human cardiac tissue, data from
animal studies strongly suggest that indeed ER stress is involved in
the induction of apoptosis and that this mechanism is enhanced by
lipid accumulation.
3.2.5 Systemic and local inflammation
It is well established that obesity and type 2 diabetes are characterized
by a state of low-grade inflammation.122,123 Systemic low-grade
inflammation influences cellular processes in all tissues, including the
heart and may lead to fibrosis and structural remodelling, which
may contribute to the cardiac stiffness/diastolic impairment observed
in diabetic cardiomyopathy.
Epicardial adipose tissue has been identified as an active source of
adipokines and cytokines.124 Due to the close relationship between
this fat depot and the myocardial tissue, coupled with the lack of
fascial boundaries, epicardial adipose tissue may locally interact and
modulate the myocardium through secretion of pro- and anti-
inflammatory cytokines.125 Epicardial adipose tissue serves as a
buffer for the storage of FFAs for the heart. However, the increased
epicardial thickness as seen in obesity has been associated with
pro-inflammatory cytokine production.126 Thereby, epicardial
adipose tissue derived cytokines may significantly contribute to the
development of diabetic cardiomyopathy.
4. Implications and conclusions
In conclusion, accumulation of fat and a higher availability of FFAs are
associated with an impaired cardiac efficiency and lipoapoptosis.
Though many of the theories are confirmed in animal models, the evi-
dence from human studies remains scarce. Nevertheless, the available
data points toward the need for lipid lowering strategies to reduce
ectopic fat accumulation and minimize lipotoxicity. To unravel the
aetiology of diabetic cardiomyopathy in humans, novel non-invasive
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imaging techniques will become increasingly important for in vivo
investigations.
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